Pacritinib Well Tolerated and Helpful in Myelofibrosis

Compared with the best available therapy for myelofibrosis, pacritinib significantly reduces spleen volume and curbs symptoms, according to results from the PERSIST-1 trial. 

 Medscape Oncology

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.